Pearl Therapeutics Announces Positive Results From Phase 2a Trial Of Formoterol Inhalation Aerosol In Chronic Obstructive Pulmonary Disease
Pearl Therapeutics Inc., a company developing high-quality combination therapies for the treatment of highly prevalent chronic respiratory diseases, announced positive results from its first clinical trial in patients with chronic obstructive pulmonary disease (COPD)…
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.